Paeoniflorininhibits systemic inflammation and improves survival in experimental sepsis

Basic and Clinical Pharmacology and Toxicology

Volumn 105, Issue 1, 2009, Pages 64-71

  Jiang, Wang Lin ^a,b   Chen, Xi Guang ^a   Zhu, Hai Bo ^b   Gao, Yu Bai ^b   Tian, Jing Wei ^c   Fu, Feng Hua ^c  

^a OCEAN UNIVERSITY OF CHINA   (China)

^b Shandong Engineering Research Center for Nature Drug   (China)

^c YANTAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; ENZYME; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B KINASE; IMIPENEM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; PAEONIFLORIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; AUTACOID; BENZOIC ACID DERIVATIVE; BRIDGED COMPOUND; DNA BINDING PROTEIN; GLUCOSIDE; IMMUNOGLOBULIN RECEPTOR; LACTIC ACID; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; TREM1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTISEPSIS; ARTICLE; CECUM; CELL CULTURE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HEMODYNAMICS; LETHALITY; LIGATION; LIVER; LUNG; MALE; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUNCTURE; RAT; SEPSIS; SMALL INTESTINE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; ENZYME ASSAY; ENZYMOLOGY; INFLAMMATION; INJURY; MACROPHAGE; METABOLISM; MORTALITY; MOUSE; PATHOLOGY; PHYSIOLOGY; SEPTIC SHOCK; SPRAGUE DAWLEY RAT; UREA NITROGEN BLOOD LEVEL;

RATTUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOIC ACIDS; BLOOD UREA NITROGEN; BRIDGED COMPOUNDS; CECUM; CELL LINE; CLINICAL ENZYME TESTS; DNA-BINDING PROTEINS; ENDOTOXINS; GLUCOSIDES; HEMODYNAMICS; IMIPENEM; INFLAMMATION; INFLAMMATION MEDIATORS; INTESTINE, SMALL; LACTIC ACID; LIVER; LUNG; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; SHOCK, SEPTIC;

EID: 67651214061     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00415.x     Document Type: Article

References (36)

1. Bochud PY, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. Br Med J 2003 326 : 262 6.
2. Bone RC. Pathophysiology of sepsis. Ann. Intern. Med 1991 115 : 457 69.
3. Yethon JA, Whitfield C. Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria. Curr Drug Targets Infect Disord 2001 1 : 91 106.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 29 : 1303 10.
5. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999 27 : 1421 8.
6. Cohen J. The immunopathogenesis of sepsis. Nature 2002 420 : 885 91.
7. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999 285 : 248 51.
8. Andersson U, Tracey KJ. HMGB1 in sepsis. Scand J Infect Dis 2003 35 : 577 84.
9. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001 164 : 1768 73.
10. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999 19 : 5237 46.
11. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003 101 : 2652 60.
12. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D et al. High Mobility Group Box 1 protein (HMGB1) interacts with multiple Toll like receptors. Am J Physiol Cell Physiol 2006 290 : 917 24.
13. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005 61 : 1 9. (Pubitemid 40188342)
14. Liu DZ, Xie KQ, Ji XQ, Ye Y, Jiang CL, Zhu XZ. Neuroprotective effect of paeoniflorin on cerebral ischemic rat by activating adenosine A1 receptor in a different manner from its classical agonists. Br J Pharmacol 2005 146 : 604 611. (Pubitemid 41487077)
15. Yamahara J, Yamada T, Kimura H, Sawada T, Fujimura H. Biologically active principles of crude drugs. II. Anti-allergic principles in 'Shoseiryu-To' anti-inflammatory properties of paeoniflorin and its derivatives. J Pharmacobiodyn 1982 5 : 921 9.
16. Hsu FL, Lai CW, Cheng JT. Antihyperglycemic effects of paeoniflorin and 8-debenzoylpaeoniflorin, glucosides from the root of Paeonia lactiflora. Planta Medica 1997 63 : 323 5.
17. Sugishita E, Amagaya S, Ogihara Y. Studies on the combination of Glycyrrhizae Radix in Shakuyakukanzo-To. J Pharmacol Bio Dyn 1984 7 : 427 35.
18. 2+ mobilization in the nerve-stimulated skeletal muscle of mice. Jap J Pharmacol 1996 69 : 281 4.
19. Takeda S, Isono T, Wakui Y, Matsuzaki Y, Sasaki H, Amagaya S, et al. Absorption and excretion of paeoniflorin in rats. J Pharm Pharmacol 1995 47 : 1036 40.
20. Lai CW, Hsu FL, Cheng JT. Stimulatory effect of paeoniflorin on adenosine A-1 receptors to increase the translocation of protein kinase C (PKC) and glucose transporter (GLUT 4) in isolated rat white adipocytes. Life Sci 1998 62 : 1591 5.
21. Jaccard CN, Troillet S, Harbarth G, Zanetti. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob. A gents Chemother 1998 42 : 2966 72.
22. Won JH, Kim YH, Yun KJ, Park HJ, Choi JW, Lee KT. Anti-inflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-κB inactivation. Br. J Pharmacol 2006 148 : 216 25.
23. Wang Y, Chen T, Han C, He D, Liu H, An H et al. Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. Blood 2007 110 : 962 971. (Pubitemid 47267435)
24. Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, Wilson P. TREM-1 promotes survival during septic shock in mice. Eur J Immunol 2007 37 : 456 66.
25. Mansart A, Bollaert PE, Seguin C, Levy B, Longrois D, Mallie JP. Hemodynamic effects of early versus late glucocorticosteroid administration in experimental septic. Shock 2003 19 : 38 44.
26. Bradley PP, Christensen RD, Rothstein G. Cellular and extracellular myeloperoxidase in pyogenic inflammation. J. Invest. Dermatol 1982 78 : 206 9.
27. Parker SJ, Watkins PE. Experimental models of gram-negative sepsis. Br J Surg 2000 88 : 22 30. (Pubitemid 32066052)
28. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 2000 13 : 110 6.
29. Fink MP, Heard SO. Laborator models of sepsis and septicshock. J sur Res 1990 49 : 186 96.
30. Fink MP, Fiallo V, Stein KL, Gardiner WM. Systemic and regional hemodynam changes after intraperitonal endotoxin in rabbit: development of a new model of the clinical syndrome of hyperdynam sepsis. Circ Shock 1987 22 : 73 81. (Pubitemid 17115563)
31. Ching LL, Wen YH, Ch LW, Hsu TK, Yen TL. Triggering receptor expressed on myeloid cells-1 in pleural effusions: A marker of inflammatory disease. Resp Med 2007 101 : 903 9.
32. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001 410 : 1103 7.
33. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol 2003 24 : 36 43. (Pubitemid 35462111)
34. Schneider CP, Schwacha MG, Chaudry IH. The role of interleukin-10 in the regulation of the systemic inflammatory response following trauma-hemorrhage. Biochim Biophys Acta 2004 1689 : 22 32. (Pubitemid 38670499)
35. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-κB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 2005 315 : 1188 95.
36. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS. Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J Biol Chem 1999 274 : 31868 74.